As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda

Detalhes bibliográficos
Autor(a) principal: Gatti, Barbara Guimarães
Data de Publicação: 2019
Outros Autores: Sabino, Bruna Amorim, Pinheiro, Bruna Muniz, Tavares Filho, Claudiney Marques, Santos, Débora Vicente, Oliveira, Larissa Aparecida de, Chaves, Leandro Santos Ferreira
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório do Centro Universitário Braz Cubas
Texto Completo: https://repositorio.cruzeirodosul.edu.br/handle/123456789/346
Resumo: Treatment with T-CAR or CAR-T cells (T-Lymphocytes with Chimeric Antigen Receptors) is one of the methods of cancer immunotherapy and has been used for the treatment of acute lymphoblastic leukemia (ALL) and other lymphomas. Having the T lymphocyte genetically modified with a CAR molecule on the surface that acts as a specific tumor cell receptor, which increases the destructive capacity of lymphocytes, since this modified molecule has the power to cause cytotoxicity to the antigen expressed on the surface of the infected cell. This literature review aimed to highlight the difficulties of this therapy, so that in the future modifications are made in order to improve it. It had a very large success with B-cell lymphoid neoplasms (recurrent and refractory), and there is also the possibility to treat some solid cancers. Acting specifically on the recognition of CD19, which is a marker of available B lineage on the tumor surface and which is expressed throughout the cell maturation process and found in most pathologies of lineage B, it suffers cytotoxicity causing reissue in the multiplication. This treatment is made from a process called leukopheresis. However the use of this treatment have some complexities and limitations, as any cancer treatment, CAR-T therapy also has side effects and other complexities that may be corrected in the future. The study of techniques aimed at reducing adverse effects can bring promising results.
id CUB_babb075a70f46f05bb7761b0ae75944a
oai_identifier_str oai:repositorio.cruzeirodosul.edu.br:123456789/346
network_acronym_str CUB
network_name_str Repositório do Centro Universitário Braz Cubas
repository_id_str
spelling As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica agudaThe CAR-T immunotherapy complexities for patients with acute lymphoblastic leukemiaImunoterapiaImunoterapiaCD19Receptor quimérico de antígenoCNPQ::OUTROS::BIOMEDICINATreatment with T-CAR or CAR-T cells (T-Lymphocytes with Chimeric Antigen Receptors) is one of the methods of cancer immunotherapy and has been used for the treatment of acute lymphoblastic leukemia (ALL) and other lymphomas. Having the T lymphocyte genetically modified with a CAR molecule on the surface that acts as a specific tumor cell receptor, which increases the destructive capacity of lymphocytes, since this modified molecule has the power to cause cytotoxicity to the antigen expressed on the surface of the infected cell. This literature review aimed to highlight the difficulties of this therapy, so that in the future modifications are made in order to improve it. It had a very large success with B-cell lymphoid neoplasms (recurrent and refractory), and there is also the possibility to treat some solid cancers. Acting specifically on the recognition of CD19, which is a marker of available B lineage on the tumor surface and which is expressed throughout the cell maturation process and found in most pathologies of lineage B, it suffers cytotoxicity causing reissue in the multiplication. This treatment is made from a process called leukopheresis. However the use of this treatment have some complexities and limitations, as any cancer treatment, CAR-T therapy also has side effects and other complexities that may be corrected in the future. The study of techniques aimed at reducing adverse effects can bring promising results.O tratamento com células T-CAR ou CAR-T (Linfócitos T com Receptores Antígenos Quiméricos) é um dos métodos da imunoterapia do câncer, e vem sendo usado para o tratamento da Leucemia Linfoblástica Aguda (LLA) e outros linfomas. Tendo o linfócito T modificado geneticamente, com uma molécula CAR de superfície, que atua como um receptor específico da célula tumoral e que aumenta a capacidade destrutiva dos linfócitos, já que esta molécula modificada tem o poder de causar citotoxicidade ao antígeno expresso na superfície da célula infectada. Esta revisão bibliográfica teve como objetivo salientar as dificuldades dessa terapia, para que no futuro sejam feitas modificações a fim de aprimorá-la. Essa terapia teve um sucesso muito grande com neoplasias linfoides de células B (recidiva e refratária), e há a possibilidade para tratar alguns cânceres sólidos. Agindo no reconhecimento do CD19, que é um marcador de linhagem B disponível na superfície tumoral e que é expresso durante todo o processo de maturação celular e encontrado na maioria das patologias de linhagem B, sofre citotoxidade causando reemissão em sua multiplicação. O tratamento é feito a partir do sangue coletado do paciente, e dessa amostra são retiradas as células T, num processo chamado leucoferese. Todavia, o tratamento tem algumas complexidades e limitações, pois assim como todo tratamento para o câncer, a terapia também possui efeitos adversos, além de outras complexidades que poderão ser corrigidas futuramente. Oss estudo de técnicas que visam diminuir os efeitos adversos podem trazer resultados promissores.Universidade Cidade de São PauloBrasilUNICID2020-02-18T18:57:11Z2020-02-18T18:57:11Z2019-12-05info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfGATTI, Bárbara Guimarães et al. As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda. Orientadora: Flavia Enira Gomes Pereira. 2019. Trabalho de Conclusão de Curso (Graduação em Biomedicina) - Universidade Cidade de São Paulo. 2019.https://repositorio.cruzeirodosul.edu.br/handle/123456789/346porTrabalho de Conclusão de CursoGatti, Barbara GuimarãesSabino, Bruna AmorimPinheiro, Bruna MunizTavares Filho, Claudiney MarquesSantos, Débora VicenteOliveira, Larissa Aparecida deChaves, Leandro Santos Ferreirainfo:eu-repo/semantics/openAccessreponame:Repositório do Centro Universitário Braz Cubasinstname:Centro Universitário Braz Cubas (CUB)instacron:CUB2020-03-30T15:10:24Zoai:repositorio.cruzeirodosul.edu.br:123456789/346Repositório InstitucionalPUBhttps://repositorio.brazcubas.edu.br/oai/requestbibli@brazcubas.edu.bropendoar:2020-03-30T15:10:24Repositório do Centro Universitário Braz Cubas - Centro Universitário Braz Cubas (CUB)false
dc.title.none.fl_str_mv As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda
The CAR-T immunotherapy complexities for patients with acute lymphoblastic leukemia
title As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda
spellingShingle As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda
Gatti, Barbara Guimarães
Imunoterapia
Imunoterapia
CD19
Receptor quimérico de antígeno
CNPQ::OUTROS::BIOMEDICINA
title_short As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda
title_full As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda
title_fullStr As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda
title_full_unstemmed As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda
title_sort As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda
author Gatti, Barbara Guimarães
author_facet Gatti, Barbara Guimarães
Sabino, Bruna Amorim
Pinheiro, Bruna Muniz
Tavares Filho, Claudiney Marques
Santos, Débora Vicente
Oliveira, Larissa Aparecida de
Chaves, Leandro Santos Ferreira
author_role author
author2 Sabino, Bruna Amorim
Pinheiro, Bruna Muniz
Tavares Filho, Claudiney Marques
Santos, Débora Vicente
Oliveira, Larissa Aparecida de
Chaves, Leandro Santos Ferreira
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Gatti, Barbara Guimarães
Sabino, Bruna Amorim
Pinheiro, Bruna Muniz
Tavares Filho, Claudiney Marques
Santos, Débora Vicente
Oliveira, Larissa Aparecida de
Chaves, Leandro Santos Ferreira
dc.subject.por.fl_str_mv Imunoterapia
Imunoterapia
CD19
Receptor quimérico de antígeno
CNPQ::OUTROS::BIOMEDICINA
topic Imunoterapia
Imunoterapia
CD19
Receptor quimérico de antígeno
CNPQ::OUTROS::BIOMEDICINA
description Treatment with T-CAR or CAR-T cells (T-Lymphocytes with Chimeric Antigen Receptors) is one of the methods of cancer immunotherapy and has been used for the treatment of acute lymphoblastic leukemia (ALL) and other lymphomas. Having the T lymphocyte genetically modified with a CAR molecule on the surface that acts as a specific tumor cell receptor, which increases the destructive capacity of lymphocytes, since this modified molecule has the power to cause cytotoxicity to the antigen expressed on the surface of the infected cell. This literature review aimed to highlight the difficulties of this therapy, so that in the future modifications are made in order to improve it. It had a very large success with B-cell lymphoid neoplasms (recurrent and refractory), and there is also the possibility to treat some solid cancers. Acting specifically on the recognition of CD19, which is a marker of available B lineage on the tumor surface and which is expressed throughout the cell maturation process and found in most pathologies of lineage B, it suffers cytotoxicity causing reissue in the multiplication. This treatment is made from a process called leukopheresis. However the use of this treatment have some complexities and limitations, as any cancer treatment, CAR-T therapy also has side effects and other complexities that may be corrected in the future. The study of techniques aimed at reducing adverse effects can bring promising results.
publishDate 2019
dc.date.none.fl_str_mv 2019-12-05
2020-02-18T18:57:11Z
2020-02-18T18:57:11Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv GATTI, Bárbara Guimarães et al. As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda. Orientadora: Flavia Enira Gomes Pereira. 2019. Trabalho de Conclusão de Curso (Graduação em Biomedicina) - Universidade Cidade de São Paulo. 2019.
https://repositorio.cruzeirodosul.edu.br/handle/123456789/346
identifier_str_mv GATTI, Bárbara Guimarães et al. As complexidades na imunoterapia T-CAR para pacientes com leucemia limfoblástica aguda. Orientadora: Flavia Enira Gomes Pereira. 2019. Trabalho de Conclusão de Curso (Graduação em Biomedicina) - Universidade Cidade de São Paulo. 2019.
url https://repositorio.cruzeirodosul.edu.br/handle/123456789/346
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv Trabalho de Conclusão de Curso
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Cidade de São Paulo
Brasil
UNICID
publisher.none.fl_str_mv Universidade Cidade de São Paulo
Brasil
UNICID
dc.source.none.fl_str_mv reponame:Repositório do Centro Universitário Braz Cubas
instname:Centro Universitário Braz Cubas (CUB)
instacron:CUB
instname_str Centro Universitário Braz Cubas (CUB)
instacron_str CUB
institution CUB
reponame_str Repositório do Centro Universitário Braz Cubas
collection Repositório do Centro Universitário Braz Cubas
repository.name.fl_str_mv Repositório do Centro Universitário Braz Cubas - Centro Universitário Braz Cubas (CUB)
repository.mail.fl_str_mv bibli@brazcubas.edu.br
_version_ 1798311351261593600